Jeremy B. Hayden Sells 5,055 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 5,055 shares of the stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $6.21, for a total transaction of $31,391.55. Following the completion of the sale, the insider now directly owns 163,565 shares in the company, valued at $1,015,738.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Sight Sciences Trading Up 0.5 %

Shares of NASDAQ:SGHT opened at $6.19 on Friday. Sight Sciences, Inc. has a one year low of $1.04 and a one year high of $9.31. The company has a debt-to-equity ratio of 0.31, a current ratio of 13.01 and a quick ratio of 12.42. The company’s fifty day moving average price is $6.09 and its 200-day moving average price is $5.26.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). The firm had revenue of $19.27 million during the quarter, compared to analysts’ expectations of $18.34 million. Sight Sciences had a negative return on equity of 44.45% and a negative net margin of 67.18%. As a group, analysts anticipate that Sight Sciences, Inc. will post -1.13 EPS for the current year.

Wall Street Analysts Forecast Growth

SGHT has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Friday, May 3rd. Piper Sandler restated a “neutral” rating and set a $6.00 target price (up from $5.00) on shares of Sight Sciences in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Sight Sciences has an average rating of “Hold” and a consensus price target of $4.70.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. UBS Group AG boosted its stake in shares of Sight Sciences by 20,282.6% in the 4th quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock valued at $14,943,000 after purchasing an additional 2,881,750 shares in the last quarter. Jackson Square Partners LLC lifted its stake in Sight Sciences by 12.0% in the fourth quarter. Jackson Square Partners LLC now owns 1,629,746 shares of the company’s stock worth $8,409,000 after purchasing an additional 174,737 shares during the last quarter. Vanguard Group Inc. boosted its position in Sight Sciences by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock valued at $8,218,000 after buying an additional 81,768 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Sight Sciences by 25.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after buying an additional 76,549 shares during the period. Finally, RTW Investments LP bought a new position in shares of Sight Sciences during the fourth quarter valued at about $850,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.